Rybelsus for Prediabetes: Evidence, Eligibility, Coverage
Rybelsus is not FDA approved for prediabetes. It is approved for type 2 diabetes and heart risk. Some doctors prescribe it when one of those uses also applies. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.
- Active ingredient
- semaglutide
- How it is taken
- daily tablet
- Approved for
- Type 2 diabetes and heart risk
- Best result (STEP 1)
- 14.9% weight loss
Key facts about Rybelsus
The half-life is about 1 week. Half of the drug is gone after 7 d; five half-lives later (35 d), about 3% is left.
Type 2 diabetes trial PIONEER 1: after 26 weeks, 3.7 kg of weight loss on the drug, compared with 1.4 kg taking placebo.
Prices each month in US dollars: the list price plus self-pay offers, all taken from the maker's price page.
Sources: FDA label (DailyMed), healthsystemtracker.org, Novo Nordisk pricing, Novo Nordisk.
Who qualifies?
| Who sets the rule | Who qualifies |
|---|---|
| FDA label | It lowers blood sugar for adults with type 2 diabetes who use it along with diet and exercise. |
| FDA label | For adults with type 2 diabetes who are at high risk, taking this medicine lowers the chance of a heart attack, a stroke, or death tied to the heart. |
| Typical commercial plan (Aetna policy) | BMI 30 or higher |
| Typical commercial plan (Aetna policy) | BMI 27 or higher with a weight-related condition |
| Typical commercial plan (Aetna policy) | a diet and activity program that lasts 6 months comes first |
Taken from FDA label (DailyMed) and aetna.com.
Prediabetes: what trials found
None of the trials enrolled only people with prediabetes. The people in them were adults who had obesity or were overweight, and none had diabetes.
| Trial | Medicine | Who took part | Length | People | Main result | Comparison |
|---|---|---|---|---|---|---|
| STEP 1 |  Wegovy | Adults with obesity or overweight, without diabetes | 68 weeks | 1,961 | 14.9% weight loss | 2.4% on placebo |
| OASIS 4 | Wegovy | Adults with obesity or overweight, without diabetes | 64 weeks | 307 | 13.6% weight loss | 2.4% on placebo |
Source of the trial: STEP 1 (FDA label (DailyMed)).
What is different for prediabetes?
| What changes | What the label says |
|---|---|
| Hypoglycemia when taken with insulin secretagogues or insulin | Low blood sugar is more likely with insulin or a sulfonylurea taken alongside it, and those doses may need to be reduced. |
| Taken with insulin or sulfonylureas | Low blood sugar is more likely with insulin or a sulfonylurea, such as glipizide or glimepiride, taken alongside this medicine, and the doctor may lower those doses. |
The FDA labels are the source of these points: FDA (DailyMed) label.
Warnings from the label: FDA label (DailyMed).
Your coverage with prediabetes
For a GLP-1 used only for weight loss, Medicare Part D pays nothing.
Where Medicaid covers weight-loss GLP-1s, prior authorization is the norm.
Sources: humana.com, KFF.
Alternatives for prediabetes
| Medicine | For prediabetes | How it is taken | Trial result |
|---|---|---|---|
| Rybelsus | Not a listed use | daily tablet | Not listed |
 Ozempic | Not a listed use | weekly injection | Not listed |
| Wegovy | Not a listed use | weekly injection or daily tablet | 14.9% weight loss |
 Mounjaro | Not a listed use | weekly injection | Not listed |
 Zepbound | Not a listed use | weekly injection | 20.9% weight loss |
 Foundayo | Not a listed use | daily tablet | 11.1% weight loss |
 Trulicity | Not a listed use | weekly injection | Not listed |
 Saxenda | Not a listed use | daily injection | 7.4% weight loss |
 Victoza | Not a listed use | daily injection | Not listed |
| Byetta | Not a listed use | twice-daily injection | Not listed |
Sources: FDA label (DailyMed).
Questions to ask your prescriber
- For my coverage, is prediabetes counted as a weight-related condition?
- Is a weight-loss brand a better fit for me than a diabetes brand?
Read the Rybelsus prescribing information on DailyMed for the complete label.